Searchable abstracts of presentations at key conferences in endocrinology

ea0086p255 | Neuroendocrinology and Pituitary | SFEBES2022

Pituitary mass and Pan hypopituitarism- A rare case of Langerhans Cell Histiocytosis

Hassaan Pervez Muhammad , Abouglila Kamal

Langerhans cell Histiocytosis is a rare neoplastic histiocytic disorder. It has broad spectrum of clinical presentations from single system to multi system. It mainly affects children but can occur in adults. It can present with skin lesions, skull/jaw tumours, polyuria/polydipsia, fever, cough and dyspnea, bone pain, ataxia etc. 25% of adult cases involve Pituitary (anterior and posterior pituitary gland) and hypothalamus. BRAF and MAP2K1 mutations are most ...

ea0077lb38 | Late Breaking | SFEBES2021

An interesting case of Hypophosphataemia: Oncogenic Osteomalacia

Pervez Muhammad Hassaan , Pearce Simon , Artham Satish

Introduction: Causes of hypophosphataemia include reduced intestinal absorption, inadequate intake, transcellular shifts (refeeding syndrome, glucose/insulin infusion), renal loss which is either FGF23 mediated (inherited forms or tumour induced osteomalacia) or non-FGF23 mediated (hyperparathyroidism, drugs)Case report: We present a case of 51 years old female referred to us with multiple fractures during her half marathon. She suffered from bilateral m...

ea0086p197 | Endocrine Cancer and Late Effects | SFEBES2022

Immunotherapy and its impact on the endocrine system: Guidelines a need of the hour

Kirty Kaushiki , Mada Shrikanth , Pervez Muhammad

Introduction: Endocrine dysfunctions are a well known side effect of Immunotherapy with check point inhibitors. Endocrine dysfunction can begin as early as 6 days post initiation of therapy. There is a growing consensus that prompt recognition and early management of these endocrinopathies is essential; however there is a lack of specific guidelines regarding the monitoring of endocrine function. We present a case report of an asymptomatic patient known to have renal cell canc...

ea0086p107 | Neuroendocrinology and Pituitary | SFEBES2022

Severe hyponatremia-A manifestation of new Pituitary metastases in Renal Cell Cancer

Abouglila Kamal , Hassaan Pervez Muhammad , Owaydah Amal

It is very rare to have Pituitary metastasis in Renal Cell cancer (RCC). Prevalence of Pituitary metastasis varies from 1-4% in all cancers and about 2.6% in RCC. Most common cancers with pituitary metastasis are breast (33%) and lung (36%). We present a rare case of RCC with pituitary Metastasis presented with severe Hyponatraemia. A 71 years old male with history of renal cell cancer who underwent Right nephrectomy in 2017. He was found to have intrathoracic metastases in 20...

ea0090p108 | Endocrine-related Cancer | ECE2023

Hypothalamic-pituitary endocrine surveillance among childhood and young-adult cancer survivors

Mamoojee Yaasir , Hossen Salman , Hassaan Pervez Muhammad

Introduction: Survivors of childhood, adolescent or young adult cancers are at risk of endocrine dysfunction from their tumours, surgery, chemotherapy and/or radiotherapy treatment. The hypothalamic pituitary axes and gonads are at risk of dysfunction depending on a number of risk factors. Endocrine dysfunction can occur from before diagnosis of cancer, soon after but mostly a number of years later, even after survivors have been discharged from oncology follow-up. We aim to e...

ea0086p187 | Bone and Calcium | SFEBES2022

High Parathyroid hormone- Think out of the box!

Hassaan Pervez Muhammad , Abouglila Kamal , Kirty Kaushiki , Tang Lim

Parathyroid hormone is a polypeptide consisting of 84 amino acids. Quantification of circulating intact PTH assists in the differential diagnosis of hypercalcemia. It is important to interpret PTH results with caution and to keep in mind Immunoassays interference can also be a reason of falsely high PTH levels. We present an interesting case referred with high parathyroid hormone levels. A 74 years old female attended clinic with raised PTH levels of 11.7 pmol/l, a normal calc...

ea0090ep709 | Pituitary and Neuroendocrinology | ECE2023

Long-term Clinical Outcomes in Acromegaly

Mamoojee Yaasir , Pervez Muhammad Hassaan , James Andy , Shery Neville

Background: Acromegaly is a rare condition characterised primarily by tumourous production of excess Growth Hormone (GH) from a pituitary adenoma. Clinical management aims at normalising serum IGF1 levels within sex and age-adjusted reference parameters. Treatment options include pituitary surgery, medical therapy with somatostatin analogue (SSA), cabergoline, pegvisomant or radiotherapy. A combination of treatment modalities is common for the majority of patients.<p class...

ea0059p049 | Bone and calcium | SFEBES2018

Primary Hyperparathyroidism (PHPT) audit

Abouzaid Mona , Pervez Muhammad , Kwang Pey Yi , Taha Reem , Joshi Ashwin

Introduction: This audit was undertaken to determine whether Primary Hyperparathyroidism (PHPT) management in the clinical setting is compliant with the nine standards set of the existing PHPT pathway in the City Hospital Sunderland Foundation Trust (CHSFT). PHPT pathway was developed in (CHSFT) to allow effective management and surgical referral for this common condition in line with available national and international guidelines.Methods: Data was retr...